ReviewPharmaceuticals (Basel, Switzerland)2023
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer.ESMO open · 2025Guideline
- Basket trials in oncology: a systematic review of practices and methods, comparative analysis of innovative methods, and an appraisal of a missed opportunity.Frontiers in oncology · 2023Pooled it
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Evaluation of HER2 and Nectin-4 Expression in Primary Vaginal Cancers.International journal of molecular sciences · 2026Article
- The role of the molecular tumor board: learnings from the ROME trial.NPJ precision oncology · 2026Article
- Recent Trends in Clinical Trials for Pediatric Sarcoma in the United States: An Analysis of ClinicalTrials.gov.Children (Basel, Switzerland) · 2026Article
- Integrating Genomics, Radiomics, and Pathomics in Oncology: A Scoping Review and a Framework for AI-Enabled Surgomics.Bioengineering (Basel, Switzerland) · 2026Review
- Article
- Breaking Barriers: Immune Checkpoint Inhibitors in Breast Cancer.Pharmaceutics · 2025Review
- Targeted DNA Sequencing for Tailored Therapies in Children with Extracranial Solid Tumors.International journal of molecular sciences · 2025Article
- PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with aFuture oncology (London, England) · 2025Article
- Telomerase inhibitors TMPyP4 and BIBR 1532 show synergistic antitumor activity in combination with chemotherapeutic drugs.Scientific reports · 2025Article
- Integrating Multi-Omics in Endometrial Cancer: From Molecular Insights to Clinical Applications.Cells · 2025Review
- Clinical/pathological features and survival outcomes of extra-pulmonary neuroendocrine carcinomas: A retrospective single-center series.Journal of neuroendocrinology · 2025Article
- Agnostic Biomarkers and Molecular Signatures in Colorectal Cancer-Guiding Chemotherapy and Predicting Response.Biomedicines · 2025Review
- Leveraging RNA from DNA Extraction Lysate to Rescue "Insufficient" Samples for More Comprehensive Genomic Profiling in Patients with Scant Tumor Specimens.The Journal of molecular diagnostics : JMD · 2025Article
- Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection.NPJ precision oncology · 2025Article
- Tumour-agnostic kinase inhibitors.Nature reviews. Drug discovery · 2025Review
- Machine learning for prediction of 30-day mortality in patients with advanced cancer: comparing pan-cancer and single-cancer models.ESMO real world data and digital oncology · 2025Article
- Real-World Outcomes of Molecular Tumor Board Treatment Recommendations.JCO precision oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: The oncology field has drastically changed with the advent of precision medicine, led by the discovery of druggable genes or immune targets assessed through next-generation sequencing. Biomarker-based treatments are increasingly emerging, and currently, six tissue-agnostic therapies are FDA-approved. (2) Methods: We performed a review of the literature and reported the trials that led to the approval of tissue-agnostic treatments and ongoing clinical trials currently investigating novel biomarker-based approaches. (3) Results: We discussed the approval of agnostic treatments: pembrolizumab and dostarlimab for MMRd/MSI-H, pembrolizumab for TMB-H, larotrectinib and entrectinib for NTRK-fusions, dabrafenib plus trametinib for BRAF V600E mutation, and selpercatinib for RET fusions. In addition, we reported novel clinical trials of biomarker-based approaches, including ALK, HER2, FGFR, and NRG1. (4) Conclusions: Precision medicine is constantly evolving, and with the improvement of diagnostic tools that allow a wider genomic definition of the tumor, tissue-agnostic targeted therapies are a promising treatment strategy tailored to the specific tumor genomic profile, leading to improved survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.